Show simple item record

dc.contributor.authorKrebs, Matthew G
dc.contributor.authorLopez, J
dc.contributor.authorEl-Khoueiry, A
dc.contributor.authorBang, Y
dc.contributor.authorPostel-Vinay, S
dc.contributor.authorAbida, W
dc.contributor.authorCarter, Louise
dc.contributor.authorXu, W
dc.contributor.authorIm, S
dc.contributor.authorPierce, A
dc.contributor.authorFrewer, P
dc.contributor.authorBerges, A
dc.contributor.authorCheung, A
dc.contributor.authorStephens, C
dc.contributor.authorFelicetti, B
dc.contributor.authorDean, E
dc.contributor.authorHollingsworth, S
dc.date.accessioned2019-09-11T09:09:18Z
dc.date.available2019-09-11T09:09:18Z
dc.date.issued2018en
dc.identifier.citationKrebs MG, Lopez J, El-Khoueiry A, Bang Y-J, Postel-Vinay S, Abida W, et al. Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers. Cancer Res. 2018;78(13).en
dc.identifier.doi10.1158/1538-7445.AM2018-CT026en
dc.identifier.urihttp://hdl.handle.net/10541/622034
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1158/1538-7445.AM2018-CT026en
dc.titlePhase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancersen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Christie NHS Foundation Trust and The University of Manchester Manchesteren
dc.identifier.journalCancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record